Live Breaking News & Updates on Inhibikase Therapeutics
Stay updated with breaking news from Inhibikase therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Inhibikase Therapeutics (NYSE:IKT – Free Report) had its price target trimmed by HC Wainwright from $27.00 to $23.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q4 2024 […] ....
Inhibikase Therapeutics (NYSE:IKT – Free Report) had its target price cut by HC Wainwright from $27.00 to $23.00 in a report issued on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q4 2024 earnings at ($0.37) […] ....
Inhibikase Therapeutics (NYSE:IKT – Free Report) had its price target trimmed by HC Wainwright from $27.00 to $23.00 in a research note issued to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q4 2024 earnings […] ....
Inhibikase Therapeutics (NYSE:IKT – Get Free Report) had its target price cut by HC Wainwright from $27.00 to $23.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Inhibikase Therapeutics Trading Up 7.5 % Shares of Inhibikase Therapeutics stock opened at $1.86 on Tuesday. The firm’s […] ....
Inhibikase Therapeutics (IKT) Prices 1.67M Share and Warrant Offering at $1.68/sh streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.